Dysregulation of the HGF/MET signaling axis has been described in a variety of malignant and premalignant lesions, including lung cancer, gastroesophageal cancer, hepatocellular carcinoma, breast cancer, ovarian cancer, multiple myeloma, and colorectal cancer18, 19, 20, 21, 22, 23, 24 and is associated with tumor growth, angiogenesis, invasion, and metastasis.25, 26. The gene discussed is MET; the disease is neoplasm.